Jazz Pharmaceuticals plc (JAZZ) Earnings
Jazz Pharmaceuticals plc's most recently reported earnings, recent earnings filings (8-K) and headline annual financials, sourced from SEC EDGAR.
Last reported earnings
Nov 2, 2026
From the latest earnings 8-K
Revenue • FY2025
$4.27B
▲ 4.9%YoY
Diluted EPS • FY2025
-$5.84
▼ 167.5%YoY
Reported earnings dates are based on the latest 8-K (Item 2.02) filings. The next earnings date is an estimate projected from JAZZ's historical reporting pattern, not a company-confirmed date.
Headline financials
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $4.27B | -$356.15M | — | -$5.84 | $1.3B | -10.1% | +4.9% |
| FY2024 | $4.07B | $560.12M | — | $8.65 | $1.36B | 17.6% | +6.1% |
| FY2023 | $3.83B | $414.83M | — | $6.10 | $1.07B | 15.1% | +4.8% |
| FY2022 | $3.66B | -$224.06M | — | -$3.58 | $1.24B | -1.8% | +18.3% |
Recent earnings filings
| Filed | Form | Accession |
|---|---|---|
| Nov 2, 2026 | 8-K (2.02) | 0001232524-26-000056EDGAR |
| Oct 26, 2026 | 8-K (2.02) | 0001628280-26-067275EDGAR |
| Aug 3, 2026 | 8-K (2.02) | 0001232524-26-000044EDGAR |
| May 5, 2026 | 8-K (2.02) | 0001232524-26-000024EDGAR |
| Feb 24, 2026 | 8-K (2.02) | 0001232524-26-000012EDGAR |
| Jan 12, 2026 | 8-K (2.02) | 0001193125-26-009899EDGAR |
| Nov 5, 2025 | 8-K (2.02) | 0001232524-25-000073EDGAR |
| Aug 5, 2025 | 8-K (2.02) | 0001232524-25-000061EDGAR |
Never miss a JAZZ filing.
Get an email when JAZZ files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Data as of Nov 8, 2026Source: SEC EDGAR.